Scilex Holding Company Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Scilex Holding Company (SCLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 803 shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-04-10
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was -2.20K shares.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 2.00K shares, a 99.49% decline year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was -1.86M shares, a 66855.73% decline year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was 395.00K shares.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 803.00 shares, a 82.21% decline from fiscal 2024.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 4.51K shares, a 74.36% decline from fiscal 2023.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 17.61K shares.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | -2.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -197.00 shares derived: sum of 2 quarters · filed 2026-04-10 | 803.00 shares 10-K · filed 2026-04-10 | |
| 2025-09-30 | 2.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 3.00K shares 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | 1.00K shares 10-Q · filed 2025-08-13 | |||
| 2024-12-31 | -1.86M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -1.47M shares derived: sum of 2 quarters · filed 2025-03-31 | 4.29K shares derived: sum of 3 quarters · filed 2025-03-31 | 4.51K shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 395.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | 1.87M shares derived: sum of 2 quarters · filed 2025-01-17 | 1.87M shares 10-Q · filed 2025-01-17 | 1.87M shares derived: sum of 4 quarters · filed 2025-01-17 |
| 2024-06-30 | 1.47M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 1.47M shares 10-Q · filed 2024-08-13 | 1.47M shares derived: sum of 3 quarters · filed 2024-08-13 | 1.47M shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 228.00 shares 10-Q · filed 2024-05-13 | 3.02K shares derived: sum of 2 quarters · filed 2024-05-13 | 3.02K shares derived: sum of 3 quarters · filed 2024-05-13 | 3.02K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 2.79K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 2.79K shares derived: sum of 2 quarters · filed 2024-03-12 | 2.79K shares derived: sum of 3 quarters · filed 2024-03-12 | 17.61K shares 10-K · filed 2024-03-12 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-14 | 14.82K shares 10-Q · filed 2023-11-14 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 14.82K shares 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | 14.82K shares 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | 0.00 shares 10-K · filed 2023-03-07 | |||
| 2021-12-31 | 0.00 shares 10-K · filed 2023-03-07 | |||
| 2020-12-31 | 4.17M shares 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |